Renejix CDMO Partner for Small Molecule Oral Dosage Forms Renejix CDMO Partner for Small Molecule Oral Dosage Forms

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Biophta","sponsor":"UI Investissement","pharmaFlowCategory":"D","amount":"$6.9 million","upfrontCash":"Undisclosed","newsHeadline":"BIOPHTA Raises \u20ac6.5M For Eye Disease Therapy Clinical Transition","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2024","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Biophta

    Menu

    Biophta

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Biophta

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              BIOPHTA Raises €6.5M For Eye Disease Therapy Clinical Transition

              Details:

              The financing aims to fund the first-in-human trial of breakthrough topical ophthalmic investigational product BO-001 for the the treatment of glaucoma.

              Lead Product(s): BO-001

              Therapeutic Area: Ophthalmology Product Name: BO-001

              Highest Development Status: Preclinical Product Type: Undisclosed

              Partner/Sponsor/Collaborator: UI Investissement

              Deal Size: $6.9 million Upfront Cash: Undisclosed

              Deal Type: Financing June 03, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY